Oxford BioMedica
Discover Realise

Key publications

Below is a selection of key publications of interest. A more comprehensive list can be provided on request.

Key publications relating to our products

Product and title                              Authors                      Journal Reference
OXB-201 (RetinoStat®)
EIAV vector-mediated delivery of endostatinor angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV. 
Balaggan et al. Gene Therapy (2006), 1-13
OXB-201 (RetinoStat®)
Safety and Biodistribution of an Equine Infectious Anemia Virus-Based Gene Therapy, RetinoStat®, for Age-Related Macular Degeneration.
K. Binley et al. Human Gene Therapy (2012), 23:980-991
SAR 422459
Correction of the disease phenotype in the mouse model of Stargardt disease by lentiviral gene therapy.
Kong et al. Gene Therapy (2008) 15, 1311–1320 
SAR 421869
Lentiviral gene replacement therapy of retinas in a mouse model for Usher syndrome type 1B.
Hashimoto et al.  Gene Therapy (2007), 1–11
OXB-202 (EncorStat®)
Corneal transduction to inhibit angiogenesis and graft failure. 
Murthy et al. Invest Ophthalmol Vis Sci. (2003) May;44(5):1837-42
Glaucoma-GT OXB-203 (Glaucoma-GT) 
Prostaglandin Pathway Gene Therapy for Sustained Reduction of Intraocular Pressure. 
Barraza et al. Molecular Therapy vol. 18 no. 3, 491–501 mar
OXB-102
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia.
Jarraya et al.  Sci Transl Med. (2009) Oct 14;1(2)
OXB-102
Long-term saftey and tolerability of ProSavin, a lentiviral vector-based gene therapy fpor Parkinson’s disease: a dose escalation, open-label, phase 1/2 trial. 
Stephane Palfi et al. The Lancet, vol 383, no 9923, pp1138 – 1146, 29 March (2014)
OXB-103 (MoNuDin®)
VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.
Azzouz et al. Nature. (2004) May 27; 429(6990): 413-7

Key publications relating to our LentiVector® platform technology

Title                              Authors                      Journal Reference
Development of a replication-competent lentivirus assay for dendritic cell-targeting lentiviral vectors Farley DC, McCloskey L, Thorne BA, Tareen SU, Nicolai CJ, Campbell DJ, Bannister R, Stewart HJ, Pearson LJ, Moyer BJ, Robbins SH, Zielinski L, Kim T, Radcliffe PA, Mitrophanous KA, Gombotz WR, Miskin JE, Kelley-Clarke B Mol Ther Methods Clin Dev. 2015 May 13;2:15017
Development of an Equine-Tropic Replication-Competent Lentivirus Assay for Equine Infectious Anemia Virus-Based Lentiviral Vectors Farley DC, Bannister R, Leroux-Carlucci MA, Evans NE, Miskin JE, Mitrophanous KA Hum Gene Ther Methods. 2012 Nov 2 (Epub ahead of print)
A Stable Producer Cell Line for the Manufacture of a Lentiviral Vector for Gene Therapy of Parkinson’s Disease Stewart HJ, Fong-Wong L, Strickland I, Chipchase D, Kelleher M, Stevenson L, Thoree V, McCarthy J, Ralph GS, Mitrophanous KA, Radcliffe PA. Human Gene Therapy. 2011 Mar; 22(3):357-69
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia Béchir Jarraya, Sabrina Boulet, G.Scott Ralph, Caroline Jan,Gilles Bonvento, Mimoun Azzouz, James E.Miskin, Masahiro Shin, Thierry Delzescaux, Xavier Drouot, Anne- Sophie Hérard, Denise M. Day, Emmanuel Brouillet, Susan M.Kingsman, Phillipe Hantraye, Kyriacos Mitrophanous, Nicholas D. Mazarakis, Stéphane Palfi www.sciencetranslationalmedicine.org 14 October 2009 Vol 1 issue 2 2ra4
Gene Therapy Based Lentiviral Vector Packaging and Producer Cell Lines H Stewart, K Mitrophanous, P Radcliffe Gene Therapy (2009 Jun) 16,805-14
Analysis of factor VIII mediated suppression of lentiviral vector titres P Radcliffe, F Wilkes, E Custard, G Beard, S Kingsman, K Mitrophanous Gene Ther. 2008 Feb;15(4):289-97.Epub 2007Nov 29
Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors - in vitro and in vivo implications D Farley, S Iqball, J Smith, J Miskin, S Kingsman, K Mitrophanous J Gene Med. 2007 May;9(5):345-56
Integration Site Selection by EIAVbased vectors C Hacker, C Vink, T Wardell, S Lee, P Treasure, S Kingsman, K Mitrophanous, J Miskin Mol Ther. 2006 Oct;14(4):536-45
Stable & efficient intraocular gene transfer using pseudotyped EIAV lentiviral vectors KBalaggan KS, Binley K, Esapa M, Iqball S, Askham Z, Kan O, Tschernutter M, Bainbridge JW, Naylor S, Ali RR J Gene Med. 2006 Mar;8(3):275-85
A replication competent lentivirus (RCL) assay for equine infectious anaemia virus (EIAV)-based lentiviral vectors Miskin J, Chipchase D, Rohll J, Beard G, Wardell T, Angell D, Roehl H, Jolly D, Kingsman S, Mitrophanous K. Gene Ther. 2006 Feb;13(3):196-205
Comparison of HIV- and EIAV - based vectors on their efficiency in transducing murine and human hematopoietic repopulating cells Siapati EK, Bigger BW, Miskin J, Chipchase D, Parsley K L, Mitrophanous K, Themis M, Thrasher A J, Bonnet D. Mol Ther. 2005 Sep;12(3):537-46
Lentiviral-mediated silencing of mutant SOD1 using RNAi prevents neurodegeneration and prolongs survival in a transgenic mouse model of ALS G Ralph, P Radcliffe, D Day, J Carthy, S Kingsman, K Mitrophanous, N Mazarakis, M Azzouz Nat Med. 2005 Apr;11(4):429-33. Epub 2005 Mar 13

Key publications relating to OXB-301 (TroVax®)

Title                              Authors                      Journal Reference
Vaccination of castration-resistant prostate cancer patients with TroVax (MVA–5T4) in combination with docetaxel: a randomized phase II trial Richard Harrop • Franklin Chu • Nashat Gabrail • Sandy Srinivas • Daniel Blount • Anna Ferrari Cancer Immunology Immunotherapy 2013 Sep;62(9):1511-20
Identification of Pre-Treatment Markers Predictive of Treatment Benefit for the Therapeutic Cancer Vaccine MVA-5T4 (TroVax). Harrop, R., Treasure, P., de Belin J., Kelleher M., Bolton, G., Naylor, S. and Shingler W. Cancer Immunology Immunotherapy 2012 61;12 2283-2294
MVA-5T4 Induced Immune Responses are an Early Marker of Efficacy in Renal Cancer Patients. Harrop, R., Shingler W., McDonald, M., Treasure, P., Amato, RJ., Hawkins, RE., Kaufman, HL., de Belin J., Kelleher M. and Naylor, S.. Cancer Immunology Immunotherapy 2011;60:829-837
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, McDonald M, Eastty S, Shingler WH, de Belin J, Goonewardena M, Naylor S, Harrop R. Clinical Cancer Research 2010;16(22):5539-47
Cross-Trial Analysis of Immunological and Clinical Data Resulting from Phase I and II Trials of MVA-5T4 (TroVax®) in Colorectal, Renal and Prostate Cancer Patients. Harrop, R., Shingler WH., Kelleher M., de Belin J. and Treasure P. Journal of Immunotherapy 2010; 33(9):999-1005
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. Amato RJ, Shingler W, Goonewardena M, de Belin J, Naylor S, Jac J, Willis J, Saxena S, Hernandez-McClain J, Harrop R. Journal of Immunotherapy. 2009; 32(7):765-72
Vaccination of patients with metastatic renal cancer with modified Vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside Interferon-α. Hawkins, R. Macdermott C., Shablak, A., Hamer C., Thistlethwaite F., Drury N., Chikoti P., Shingler W., Naylor S. and Harrop, R. Journal of Immunotherapy 2009; 32(4):424-9
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, Deraffele G, Mitcham J, Carroll MW, Harrop R, Naylor S, Kim-Schulze S. Journal of Translational Medicine. 2009; Jan 7;7(1):2
Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) administered with IL-2:  A Phase II Trial. Amato RJ, Shingler, W., Naylor, S., Jac, J., Willis, J., Saxena, S., Hernandez-McClain, J. and Harrop R. Clinical Cancer Research 2008; 14(22):7504-10
Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): a phase 2 trial. Amato RJ, Drury N, Naylor S, Jac J, Saxena S, Cao A, Hernandez-McClain J and Harrop R. Journal of Immunotherapy 2008; 31(6):577-85
Vaccination of Colorectal Cancer Patients with Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Chemotherapy Induces Potent Immune Responses. Harrop R, Drury N, Shingler W et al. Clinical Cancer Research 2007; 13 4487-4494
Analysis of pre-treatment markers predictive of treatment benefit for the threaputic cancer vaccine MVA-5T4 (TroVax). Harrop R et al. Cancer Immunol Immunother. (2012) Dec; 61(12):2283-94
Both TroVax and Cyclophosphamide induce anti-tumour immune responses that correlate with prolonged survival of end-stage colerectal cancer patients. Scurr M et al. Cardiff University/Cancer Research Wales (2015) 

 

Facts

Research

We are world leaders in the development of lentiviral vectors and our scientists are named authors on multiple publications


Experts

We are privileged to be working alongside key opinion leaders, clinicians, academic institutions, charitable organisations and industry specialists within our chosen fields of development